China National Pharmaceutical Group Eyes $1B Acquisition of BBI Life Science to Enter Life Science Tools Market

As we just entered the second half of the year, “revenge” medical IPOs have restarted, while industry giants have also begun their frenzied acquisition sprees. In the past week alone, nearly RMB 20 billion has flowed into the life science tools sector.

Recently, Bloomberg reported that China National Pharmaceutical Group (Sinopharm), the domestic pharmaceutical giant, is preparing to spend $1 billion to acquire BBI Life Sciences. Headquartered in Shanghai, BBI is more commonly known as Sangon Biotech.

Since 1995, Sangon Biotech has been providing DNA synthesis products and services to biological laboratories and research institutions in China. In 2002, BBI was established, integrating Sangon Biotech’s equity and business operations. During the previous wave of IPOs in the life sciences sector, BBI made a brief listing on the Hong Kong Stock Exchange in 2014. Six years later, the founding team privatized BBI for HK$845 million. Since then, although there have been frequent rumors that BBI would apply for a listing on the STAR Market, what ultimately emerged was the prospect of a major industrial merger and acquisition.

“Sinopharm Group has discussed the possibility of a merger and acquisition transaction with BBI’s founding team. Meanwhile, BBI’s founding team is also in contact with other potential acquirers,” Bloomberg reported in its news article.In other words, even though Sinopharm offered a price nearly ten times the valuation at which BBI delisted two years ago, it still lacked absolute certainty of successfully acquiring the company.

In fact, on the very day after rumors emerged that BBI was poised for acquisition, another leading IVD raw material manufacturer, Medixbiochemica (Maidian), announced it would be acquired for $1.53 billion by SD Biosensor, a South Korean diagnostics company that manufactures POCT COVID-19 test kits under contract for Roche Diagnostics. These two successive blockbuster deals have once again pushed the red-hot fundraising frenzy in the life sciences tools sector to new heights.

Neither Sinopharm Group nor BBI has responded to the acquisition. However, an analysis by VCBeat reveals that the two companies have not had significant business overlap in their past operations. So, what kind of company is BBI exactly? What is the rationale behind this transaction? Will Sinopharm Group also make a push into the life sciences tools sector? We attempt to answer these questions.

Let's start with BBI.

Although its presence in the capital markets has been relatively muted, BBI has, at least at one point, qualified as a leading upstream enterprise in the life sciences tools sector based on the quality of its business operations.

In its prospectus from over eight years ago, BBI positioned itself as a renowned supplier in China’s life science research products and services industry. This self-positioning remained unchanged in its final financial report before delisting, which is quite rare in the ever-changing biotechnology sector.

Specifically, BBI provides a wide range of products and customized services for life science research through in-house development and distribution channels. These offerings include various reagents and consumables, such as biochemical reagents, molecular biology reagents, and protein science reagents, as well as antibodies, laboratory consumables, and instruments and equipment. In a sense, BBI offers researchers a one-stop solution for all experiment-related needs. Notably, customized services constitute BBI’s most fundamental and distinctive offering, encompassing DNA synthesis, RNA synthesis, gene sequencing, and nucleic acid-protein interaction analysis.

In China, the companies with business lines most similar to BBI include molecular biological reagent manufacturers such as Vazyme, Kangwei Century, and Hanhai New Enzyme. Previously, BBI was on par with GenScript in the DNA synthesis business. As GenScript has continuously expanded into more complex areas such as cell therapy and CDMO, the competitive relationship between the two has gradually weakened. In terms of business volume, BBI’s scale is significantly larger than that of Kangwei Century and Hanhai New Enzyme, but it remains smaller than that of Vazyme, which has already expanded into downstream IVD and biopharmaceutical businesses.

The core life sciences tools sector, where BBI operates, is a market segment where blockbuster products are rare, involving a wide variety of products and technologies. Major manufacturers typically leverage their strong industrialization capabilities in specific technologies to continuously expand their SKU portfolios, thereby building brand influence. For instance, Vazyme and Hanhai New Enzyme excel in enzyme technology, while Sino Biological and Nearshore Protein have grown stronger and larger by focusing on recombinant proteins.

BBI’s core competency is oligonucleotide synthesis, with particular expertise in synthesizing complex and rare oligonucleotides.

In the absence of more recent authoritative data, we can only infer BBI’s position in the oligonucleotide synthesis market based on 2013 figures. In 2013, BBI was the largest domestic supplier of DNA synthesis products, with oligonucleotide sales revenue reaching RMB 63.7 million and capturing a 26% market share—more than the combined total of the four competitors ranked second through fifth. It is an objective fact that while oligonucleotide synthesis is grounded in well-established nucleic acid chemistry principles, the industry still heavily relies on technical expertise, accumulated experience, distribution channels, and brand reputation. BBI’s first-mover advantage may help it maintain its leading market position to some extent.

At present, the demand for synthetic oligonucleotides in the life sciences community continues to rise. This is because they are key raw materials for gene synthesis, which serves as the starting point for gene therapy.

Synthetic oligonucleotides are synthesized from nucleic acid monomers via DNA synthesis and serve as critical foundational materials in most biotechnology experiments. The products of DNA synthesis include both oligonucleotides and gene sequences, which differ primarily in the length of the resulting nucleic acid molecules.

Among these, oligonucleotide synthesis is relatively simple, involving the chemical synthesis of short, single-stranded nucleic acids with desired sequences, and serves as a key foundation for nucleic acid amplification, detection, and analysis. For instance, oligonucleotides are used as primers in DNA sequencing and amplification, or as probes in DNA and RNA detection. They are also employed to synthesize gene fragments with specific sequences.

Gene synthesis requires oligonucleotides as raw materials and involves multiple complex operations and enzymatic reactions, including amplification, cloning, purification, and error correction, to generate long, double-stranded nucleic acids with specific sequences. In comparison, synthetically produced genes have broader application scenarios, including genetic research, regulation of gene expression, and gene and drug discovery.

For instance, in the production of gene therapy drugs, the first step is to synthesize the target gene sequence, which is then packaged into plasmids for transfecting vectors such as adeno-associated virus (AAV), adenovirus, and lentivirus. This process yields recombinant viruses that are subsequently cultured in vitro, purified, and subjected to quality control to produce the bulk drug substance intended for clinical injection. Currently, gene therapy is in an accelerated phase of commercialization. According to Frost & Sullivan, the market size of gene therapy in China is projected to grow from RMB 268 million in 2021 to RMB 17.9 billion in 2025, representing a compound annual growth rate (CAGR) of 276%.

Thus, it is evident that oligonucleotides have become a standard staple in the vast majority of life science laboratories worldwide, both currently and for the foreseeable future. For Sinopharm, the acquisition of BBI amounts to securing a critical entry ticket into the life sciences tools industry.

A key backdrop to Sinopharm Group’s proposed acquisition of BBI is that the life sciences tools sector, in which BBI operates, has been the most sought-after track for medical innovation in China over the past two years.

Over the past two years, tens of billions in capital have flowed into innovation in life science tools. Since the second half of 2020, a large number of domestic brands that have established prominence in fields such as antigens/antibodies, enzymes, bioreactors, and cell culture media have rapidly entered a fast track for business expansion and external financing.

According to incomplete statistics from the Arterial Orange database, since March 2020, at least 20 life science tools companies have completed two or more rounds of financing, with transaction amounts continuously reaching new highs. For instance, Aobios, a leading domestic cell culture media company, completed four rounds of financing within two years, raising over RMB 2.5 billion. Jinyi Shengshi, which provides single-use bioprocess total solutions for companies such as CanSino Biologics, completed three rounds of financing totaling hundreds of millions of yuan within just one year, setting a new record for the speed of fundraising among life science tools companies. Notably, during this period, Bioprocyte, Nanomicro Tech, Sino Biological, and Vazyme successfully completed their initial public offerings (IPOs), while Fapon Biotech, Kangwei Century, Nearshore Protein, and Lianchuan Biology are also poised to launch their IPOs.

Interestingly, beyond business expansion and valuation-driven capital attraction, some star enterprises in the life sciences tools sector have even begun acting as limited partners (LPs). Previously, ACROBiosystems announced its intention to subscribe to shares of a US dollar-denominated fund with no more than $2 million in self-owned funds, primarily targeting investments in biotechnology, life sciences, and the broader health industry. Similarly, Vazyme and Fapon Biotech have also quietly made strategic allocations into professional equity investment funds. This trend may well signal the maturation of China’s life sciences tools industry.

Underlying this is the rapid expansion of the life sciences services market itself.

On the one hand, over the past few years, the global biopharmaceutical innovation industry, as a downstream sector of life science tools, has become the most prominent hotspot for capital attraction, with over $1 trillion in funds injected within a short period. According to Frost & Sullivan statistics, global pharmaceutical companies’ R&D expenditures reached $187.8 billion in 2020, while the R&D spending of large-scale enterprises in China’s biopharmaceutical industry amounted to RMB 78.5 billion, representing a year-on-year increase of 28.7%. This has driven continuous growth in demand for biological scientific services. The substantial investments made in exploring areas such as mRNA vaccines and cell and gene therapy have further contributed additional incremental expansion to this industry. According to projections by Soochow Securities, excluding laboratory equipment,In 2020, the overall market size of life science tools in China exceeded RMB 60 billion. From 2020 to 2024, this market is expected to continue growing at a compound annual growth rate (CAGR) of 20%.

On the other hand, in the post-COVID-19 era,Proven domestic life science tool manufacturers are accelerating the replacement of imported brands with high-quality products and services.. As the life sciences tools sector is a comprehensive system driven by interdisciplinary innovation, it had long been monopolized by imported brands. However, during the COVID-19 pandemic, factors such as logistics disruptions and epidemic control measures compelled midstream users to seek domestic suppliers. In China, some enterprises, after years of technological accumulation, have developed mainstream products whose performance rivals that of imported brands. Examples include enzymes provided by Vazyme, antigens supplied by Fapon Biotech, and synthetic DNA products offered by BBI Solutions. These companies rapidly responded to market demand at 50–80% of the price of imported alternatives, gradually reclaiming market share and experiencing explosive revenue growth. For instance, Vazyme’s revenue in 2020 was 5.83 times that of the previous year, while Fapon Biotech also achieved a 3.69-fold increase in revenue.

Given that life science services account for over 60% of the costs for most biotechnology companies, the growth potential for domestic life science tool enterprises remains quite substantial against the backdrop of future healthcare cost containment measures.

In previous exchanges with several investment firms, many investors told VCBeat that they have made life science tools a key focus for identifying investment targets. Some firms even hold regular internal study sessions on life science tools. “It’s no longer a question of whether to invest, but how to invest,” said one investor.

Finally, let us turn to Sinopharm. As previously mentioned, the collaboration between Sinopharm and BBI was not particularly deep prior to the emergence of merger and acquisition considerations. However, as one of only two Chinese pharmaceutical enterprises listed on the Fortune Global 500, Sinopharm’s industrial landscape does feature significant areas of alignment with BBI’s business operations and future trajectory. In VCBeat’s view, the two parties may achieve resource synergy in three key areas.

First, collaborative R&D of vaccines.Sinopharm is the largest vaccine manufacturer in China. Sinopharm oversees six major domestic biological products institutes located in Beijing, Lanzhou, Chengdu, Shanghai, Changchun, and Wuhan, serving as the national team for vaccine research and development and production. It currently has an annual production capacity of 700 million doses of human vaccines and supplies 80% of the vaccines used in China’s National Immunization Program. During the COVID-19 pandemic, one of the first inactivated vaccines to be launched in China was developed by Sinopharm’s Beijing Institute of Biological Products.

For Sinopharm, strengthening external collaborations is a strategy that leverages its comparative advantages in the development of novel vaccines. For instance, Sinopharm CNBG has partnered with Fuanjian to initiate the research and development of Omicron-variant vaccines, building upon their ongoing work on mRNA vaccines targeting the “Delta Plus” variant, with plans to complete pilot-scale trials and related studies as soon as possible. Key stages in mRNA vaccine development—including target screening, mRNA production, purification, delivery, and DNA template preparation—all involve DNA plasmids and require extensive screening and purification processes. These demands place higher requirements on DNA synthesis capabilities, an area of expertise for BBI, particularly in the R&D centers focused on other types of novel vaccines.

Next is the complementarity of channel resources.At this stage, to more precisely meet user needs, life science tool manufacturers are increasingly adopting digital marketing strategies. Previously, BBI established a strategic partnership with MOLBASE, a comprehensive e-commerce platform for chemicals, listing over 30,000 products from its three proprietary brands—BBI, Sangon Biotech, and Diamond—on the MOLBASE Laboratory Supplies Mall. Leveraging digital tools such as big data and neural networks, the collaboration aims to provide cost-effective life science tools for mid-to-high-end scientific research and industrial R&D. Meanwhile, Sinopharm Chemical Reagent Network, a subsidiary of Sinopharm Group, is a leading domestic provider of laboratory products and services. It integrates chemical reagents, biological reagents, laboratory consumables, and testing equipment from multiple brands, and even offers comprehensive solutions for laboratory construction, thereby facilitating BBI’s digital marketing efforts.

Finally, there is the synergy of the industrial ecosystem.This is primarily based on the vast medical innovation ecosystem established through Sinopharm Capital’s equity investments. Originating from Sinopharm Group, Sinopharm Capital was one of the earliest private equity firms in China to focus exclusively on healthcare and wellness investments. Since its inception, the firm has managed seven funds with total assets under management exceeding RMB 6.5 billion, comprehensively covering early-stage innovative ventures, growth-stage companies, and merger and acquisition integration projects.

Sinopharm Capital has invested in nearly 80 star enterprises in the big health sector, including Sinopharm Dental, Genor Biopharma, Allist Pharmaceuticals, Linko Pharma, GenePharma, Senyi Intelligence, Sepax Technologies, iDea Technology, Juyi Technology, Xiantong Medicine, and ClearMab Biotechnology. Within Sinopharm Capital’s investment ecosystem, there are companies operating in the same life science tools segment as BBI, such as Sepax Technologies, as well as potential customer groups, such as Genor Biopharma and ClearMab Biotechnology. The resulting business synergies will undoubtedly help BBI rapidly establish stronger competitive capabilities following its acquisition.

Of course, everything remains speculative until the final equity transfer is formally completed. Nevertheless, we sincerely hope that, amidst this rare historical opportunity, China’s life sciences tools industry will undergo a remarkable transformation and give rise to professional brands with global influence.